AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01164228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study NCT02440802 — intervention group
Intervention type: GENETIC
Intervention: Saliva sample collection for genetic analyses
Description: Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
Study NCT02390856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventus DRS
Description: The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
Study NCT02390856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate
Description: A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
Study NCT02565121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Study NCT02565121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory stimulation
Description: stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
Study NCT04263103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SJ-RS-WL2015 visual training program software
Description: It is a software with perceptual learning methods for binocular functions
Study NCT00671905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GP ablation
Description: HF stimulation-guided and anatomic ablation of the main right and left atrial GP
Study NCT00671905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation
Description: Circumferential PV isolation
Study NCT02801188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
Study NCT02801188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of bupivacaine and dexmedetomidine
Description: Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
Study NCT02837562 — intervention group
Intervention type: OTHER
Intervention: Slit lamp eye examination
Description: All participants in the trial will undergo a slit lamp eye examination
Study NCT04644640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
Study NCT04644640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Range of motion exercises for the knee, proprioception and balance training
Study NCT02938923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Topical testosterone gel 1%
Study NCT02938923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Inactive skin gel
Study NCT02938923 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise training
Description: Multicomponent exercise program focused primarily on progressive resistance exercise training
Study NCT02938923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Multicomponent exercise program focused primarily on progressive resistance exercise training
Study NCT02938923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home exercise program
Description: Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
Study NCT02938923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Modules
Description: 30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
Study NCT03454425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Subthalamotomy
Description: ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
Study NCT03454425 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Exablate Subthalamotomy
Description: Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
Study NCT01001949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Bran Extract
Description: soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
Study NCT01001949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
Study NCT00876460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + docetaxel M
Description: BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
Study NCT00876460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + docetaxel H
Description: BIBF 1120 Medium dose bid + docetaxel 75mg/m2
Study NCT00876460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + docetaxel H
Description: BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
Study NCT00876460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 L + docetaxel M
Description: BIBF 1120 Low dose bid + docetaxel 60 mg/m2
Study NCT00876460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + docetaxel M
Description: BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
Study NCT02765022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clip closure
Description: Complete clip closure of secondary lesions after the endoscopic mucosal resection
Study NCT02765022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No clip closure
Description: Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
Study NCT03115554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Plus Catheter Ablation
Description: Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
Study NCT03115554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Alone
Description: Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
Study NCT04255342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery
Description: At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
Study NCT02691013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Study NCT02691013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05154500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron biofortified potato
Description: A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
Study NCT02961114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
Study NCT02961114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
Study NCT02961114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV Sterile Normal Saline
Description: Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
Study NCT01147692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: simvastatin plus albiglutide
Description: A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
Study NCT02705859 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Copanlisib
Description: Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
Study NCT02705859 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
Study NCT05154500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Iron biofortified potato
Description: A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
Study NCT05154500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc biofortified potato
Description: A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
Study NCT05154500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zinc biofortified potato
Description: A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
Study NCT02409563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (100 mcg bid)
Study NCT02409563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (50 mcg bid
Study NCT03549442 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BCMA CART + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Study NCT03549442 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CART BCMA or CART BCMA + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Study NCT03549442 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Single-dose infusion of CART BCMA or CART BCMA + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Study NCT04057547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study NCT04057547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study NCT03057054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT
Study NCT03057054 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT
Study NCT03057054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299
Description: Given PO or via NJ, NG or G tube
Study NCT03057054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299v
Description: Given PO or via NJ, NG or G tube
Study NCT03057054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO or via NJ, NG or G tube
Study NCT03721055 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-(2S,4R)4-fluoroglutamine
Description: Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (600 mg, in three 200 mg hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin
Description: Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle
Study NCT02278120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
Study NCT02401516 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reprogramming insoles
Description: 1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
Study NCT02401516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reprogramming insoles
Description: 1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
Study NCT04582929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox ® Injection
Description: Neuronox ® 50 or 100 unit intramuscular injection
Study NCT03530605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune TTF device
Description: portable device which produces electrical fields
Study NCT06766786 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulfate high dose
Description: Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
Study NCT03204929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: copper-containing synthetic small molecule
Study NCT01671995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse monitored heart failure program
Description: Standard program for a heart failure clinic with information, education, drug titration
Study NCT01671995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary health care
Description: Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
Study NCT01850147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, chemotherapy
Description: sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
Study NCT02966678 — intervention group
Intervention type: PROCEDURE
Intervention: Color Vision Test
Description: Farnsworth Panel D15/Hue test plus Ishihara charts
Study NCT04245540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pau d' Arco
Description: Encapsulated herbal Pau d' Arco.
Study NCT05320783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: Classical music pre-selected was started to the patients with individual comfortable volume.
Study NCT05320783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: music player was not started.